期刊
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
卷 7, 期 6, 页码 624-632出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/187152007784111331
关键词
rational drug design; tyrosine kinases; BTK; cancer; thromboembolism
资金
- NHLBI NIH HHS [R44 HL071288-03] Funding Source: Medline
Targeting Bruton's tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors a I so exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic complications in cancer patients, This review will focus on the role of BTK in drug resistance in cancer, thromboembolism, and various pathologic immune responses, Such as graft versus host disease. The therapeutic potential of targeting BTK is illustrated by discussion of the biologic activity profile of the rationally designed BTK inhibitor LFM-Al3.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据